Best Practices and Future Directions in Paired Tumor-Normal Molecular Profiling for Solid Tumors

Program Committee Moderator(s)

• 

  Stuart Scott, PhD

  Professor, Laboratory Director
  Stanford
  Palo Alto, California, United States
• 

  Fei Dong, MD

  Associate Professor
  Stanford University
  Palo Alto, California, United States

Description: Paired tumor-normal molecular profiling is increasingly being adopted as a diagnostic strategy for patients with cancer, which is driven by its capacity to identify both somatic mutations driving the cancer and germline mutations associated with hereditary cancer predisposition. This approach has also been enabled for clinical laboratories by the ongoing advances in sequencing technologies and bioinformatic resources; however, challenges and barriers remain that limit broader adoption across cancer types. This session is aimed at highlighting the utility of germline molecular profiling coupled with somatic diagnostic sequencing in oncology, with specific focus on its implementation for solid tumor molecular diagnostics.
If this session topic is of interest to you, please consider looking at the following course on AMP EDucation (AMPED™ Online)

Title: Ancestry-Driven Recalibration of Tumor Mutational Burden and Disparate Clinical Outcomes in Response to Immune Checkpoint Inhibitors
Please Click Here to Learn More.

Presentations:

• 2:30 PM - 3:00 PM EST

  Identifying Germline Variants in Pediatric Patients With Solid Tumors
  

  Breakout Speaker: Minjie Luo, PhD (she/her/hers) – Children's Hospital of Philadelphia
• 3:00 PM - 3:30 PM EST

  Insights into Hereditary Cancer Predisposition from Tumor-Normal Sequencing: the MSK-IMPACT Experience
  

  Breakout Speaker: Diana Mandelker, MD, PhD – Memorial Sloan Kettering Cancer Center
• 3:30 PM - 4:00 PM EST

  Putting Precision Medicine into Practice for Prostate Cancer: Impact of Genetic Testing on Cancer Risk and Treatment
  

  Breakout Speaker: Patrick Pilie, MD – MD Anderson Cancer Center